Welcome to LookChem.com Sign In|Join Free
  • or
D 620 is a silicone-based chemical compound that serves as an effective defoamer in various industrial applications. It is renowned for its high stability, compatibility with a broad spectrum of liquids, and its non-toxic, environmentally friendly nature, making it a popular choice for eliminating foam formation and enhancing the efficiency of industrial processes.

27487-66-7

Post Buying Request

27487-66-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

27487-66-7 Usage

Uses

Used in Industrial Water Treatment:
D 620 is used as a defoamer to break down foam bubbles and prevent their reformation in water treatment processes, thereby improving the efficiency of the treatment system.
Used in Pulp and Paper Processing:
In the pulp and paper industry, D 620 is utilized as a defoaming agent to control and eliminate foam, ensuring smooth operation and enhancing the production process.
Used in Oil and Gas Production:
D 620 is employed as a defoamer in oil and gas extraction to mitigate foam-related issues, improving the efficiency of production and reducing the potential for equipment damage or process interruptions.

Check Digit Verification of cas no

The CAS Registry Mumber 27487-66-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,4,8 and 7 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 27487-66:
(7*2)+(6*7)+(5*4)+(4*8)+(3*7)+(2*6)+(1*6)=147
147 % 10 = 7
So 27487-66-7 is a valid CAS Registry Number.
InChI:InChI=1/C16H24N2O2/c1-12(2)16(11-18,8-5-9-17)13-6-7-14(19-3)15(10-13)20-4/h6-7,10,12H,5,8-9,17H2,1-4H3

27487-66-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-amino-2-(3,4-dimethoxyphenyl)-2-propan-2-ylpentanenitrile

1.2 Other means of identification

Product number -
Other names 2-(3,4-dimethoxyphenyl)-2-isopropyl-5-amino-pentanenitrile

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:27487-66-7 SDS

27487-66-7Relevant academic research and scientific papers

Design, synthesis and evaluation of 9-hydroxy-7H-furo [3,2-g]chromen-7-one derivatives as new potential vasodilatory agents

Wang, Cheng,Wang, Tao,Zhou, Nan,Pan, Xiao-Yan,He, Huai-Zhen

, p. 304 - 311 (2014/02/14)

Two new 9-hydroxy-7H-furo[3,2-g]chromen-7-one derivatives were designed, synthesized and evaluated for their in vitro vasodilatory activity. The structures of two compounds were elucidated by infrared, 1H NMR, and mass spectral data. The invitro pharmacological evaluation indicated that both of them possessed well vasodilatory activity compared with imperatorin. The molecule docking also showed two target compounds docked well with L-calcium channel (PDB code: 3G43). The result suggested that they would be potential vasodilatory agents for hypertension.

Comparison of triple quadrupole, hybrid linear ion trap triple quadrupole, time-of-flight and LTQ-orbitrap mass spectrometers in drug discovery phase metabolite screening and identification in vitro - amitriptyline and verapamil as model compounds

Rousu, Timo,Herttuainen, Jukka,Tolonen, Ari

experimental part, p. 939 - 957 (2011/10/19)

Liquid chromatography in combination with mass spectrometry (LC/MS) is a superior analytical technique for metabolite profiling and identification studies performed in drug discovery and development laboratories. In the early phase of drug discovery the analytical approach should be both time- and cost-effective, thus providing as much data as possible with only one visit to the laboratory, without the need for further experiments. Recent developments in mass spectrometers have created a situation where many different mass spectrometers are available for the task, each with their specific strengths and drawbacks. We compared the metabolite screening properties of four main types of mass spectrometers used in analytical laboratories, considering both the ability to detect the metabolites and provide structural information, as well as the issues related to time consumption in laboratory and thereafter in data processing. Human liver microsomal incubations with amitriptyline and verapamil were used as test samples, and early-phase 'one lab visit only' approaches were used with all instruments. In total, 28 amitriptyline and 69 verapamil metabolites were found and tentatively identified. Time-of-flight mass spectrometry (TOFMS) was the only approach detecting all of them, shown to be the most suitable instrument for elucidating as comprehensive metabolite profile as possible leading also to lowest overall time consumption together with the LTQ-Orbitrap approach. The latter however suffered from lower detection sensitivity and false negatives, and due to slow data acquisition rate required slower chromatography. Approaches with triple quadrupole mass spectrometry (QqQ) and hybrid linear ion trap triple quadrupole mass spectrometry (Q-Trap) provided the highest amount of fragment ion data for structural elucidation, but, in addition to being unable to produce very high-important accurate mass data, they suffered from many false negatives, and especially with the QqQ, from very high overall time consumption.

A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds

Sawayama, Andrew M.,Chen, Michael M. Y.,Kulanthaivel, Palaniappan,Kuo, Ming-Shang,Hemmerle, Horst,Arnold, Frances H.

supporting information; scheme or table, p. 11723 - 11729 (2010/04/29)

Herein we demonstrate that a small panel of variants of cytochrome P450 BM3 from Bacillus megaterium covers the breadth of reactivity of human P450s by producing 12 of 13 mammalian metabolites for two marketed drugs, verapamil and astemizole, and one research compound. The most active enzymes support preparation of individual metabolites for preclinical bioactivity and toxicology evaluations. Underscoring their potential utility in drug lead diversification, engineered P450 BM3 variants also produce novel metabolites by catalyzing reactions at carbon centers beyond those targeted by animal and human P450s. Production of a specific metabolite can be improved by directed evolution of the enzyme catalyst. Some variants are more active on the more hydrophobic parent drug than on its metabolites, which limits production of multiply-hydroxylated species, a preference that appears to depend on the evolutionary history of the P450 variant.

Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: Discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range

Teodori, Elisabetta,Dei, Silvia,Quidu, Patricia,Budriesi, Roberta,Chiarini, Alberto,Garnier-Suillerot, Arlette,Gualtieri, Fulvio,Manetti, Dina,Romanelli, Maria Novella,Scapecchi, Serena

, p. 1687 - 1697 (2007/10/03)

On the basis of the results obtained in previous research, three series of compounds (A-C), derived from verapamil, were designed and synthesized to obtain drugs able to revert multidrug resistance (MDR), an acquired resistance that frequently impairs cancer chemotherapy. The ability of the obtained compounds to revert MDR was evaluated on anthracycline-resistant erythroleukemia K 562 cells, measuring the uptake of THP-adriamycin (pirarubicin) by continuous spectrofluorometric monitoring of the decrease of the fluorescence signal of the anthracycline at 590 nm (λ(ex) = 480 nm), after incubation with cells. Cardiovascular activity, which is responsible for unwanted side effects, was also evaluated. The results obtained show that many of the compounds studied are potent reverters of MDR and are endowed with reduced cardiovascular activity. One of the compounds (7, MM36) presents a pharmacological profile (unprecedented nanomolar potency, high reversal of MDR, low cardiovascular activity) that makes it a promising drug candidate to treat MDR and a useful tool for studying P-glycoprotein.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 27487-66-7